ABIGAIL KAERICHERANDREW COATS — Legislative Assistant, Rep. Mark Souder.JOHN WILLIAMS — Press Secretary, House Committee on Government Reform and Oversight; Press Secretary, Rep. Dan Burton.
IDs
Filing UUID:9bd15ddc-951d-4192-baa8-b711c040b952
Registrant ID:17352
Client ID:55694
2025-10-02
GOVERNMENT COUNSEL, LLC
APOTEX CORPORATION
$20,000
$0
Filing Details
Type: ld2 • Year: 2025 Q3
Specific Issues
Federal policy relating to trade tariffs, strengthening domestic generic production and market access barriers for generic pharmaceuticals.
Government Entities
HOUSE OF REPRESENTATIVES, SENATE
Registered Lobbyists (1)
HENRY MENN — Chief of Staff, Sen. Bob Graham; Minority Staff Director & Counsel, Sen. Cmte on Veterans Affairs; Sp. Asst. Legislative Affairs, FDA Office of Commissioner.
IDs
Filing UUID:43b23449-47cd-45df-8578-b97b69c3d3f5
Registrant ID:401105070
Client ID:203130
2025-10-02
LOPER CONSULTING LLC
AMERICAN MEDICAL ASSOCIATION
$40,000
$0
Filing Details
Type: ld2 • Year: 2025 Q3
Specific Issues
H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 S. 891, Bipartisan Health Care Act; H.R. 1 One Big Beautiful Big Act; Monitoring H.R.5371 - Continuing Appropriations and Extensions Act, 2026 Equitable Community Access to Pharmacist Services Act
Government Entities
HOUSE OF REPRESENTATIVES, SENATE
Registered Lobbyists (1)
GINGER LOPER — Special Assistant to the President (2002-2005)
IDs
Filing UUID:c3d266a3-3045-4390-9fd8-d12c172ea1d5
Registrant ID:400545627
Client ID:192740
2025-10-02
REVVITY, INC.
REVVITY, INC.
$0
$30,000
Filing Details
Type: ld2 • Year: 2025 Q3
Specific Issues
Diagnostic test reimbursement and policies Genomic sequencing T-Cell Immune Response Testing Proposals related to newborn screening Newborn Screening Saves Lives Act Proposals related to pandemic preparedness FDA Medical Device Product policies H.R. 2810, Family Cord Blood Banking Act Medical Device & Pharmaceutical Adjacent Tariffs; Medical Device & Pharmaceutical Adjacent Tariff
Government Entities
Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, SENATE, Bureau of Industry and Security (BIS)
Registered Lobbyists (1)
LUIS TOVAR ●NEW
IDs
Filing UUID:cc0aade4-06d5-499a-87b9-d6e23317ea1e
Registrant ID:401105953
Client ID:208897
2025-10-01
MR. DAN CRIPPEN
AMGEN
$36,000
$0
Filing Details
Type: ld2 • Year: 2025 Q3
Specific Issues
pharmacy rebates and discounts pharmacy R&D; pharmacy rebates and discounts; congressional procedure
Discussed issues related to onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, and potential impact of tariffs on domestic biopharmaceutical manufacturing.; Discussed issues related to onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, and potential impact of tariffs on domestic biopharmaceutical manufacturing.; Discussed issues related to onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, and potential impact of tariffs on domestic biopharmaceutical manufacturing.; Discussed response to Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients
Government Entities
Bureau of Industry and Security (BIS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES
Registered Lobbyists (1)
GIL ROTH — not applicable
IDs
Filing UUID:705042af-4b1e-427a-83d1-ad7057c2900a
Registrant ID:401103605
Client ID:199773
2025-10-01
CRANE STRATEGIES
REGENERON PHARMACEUTICALS, INC.
$50,000
$0
Filing Details
Type: ld2 • Year: 2025 Q3
Specific Issues
Biodefense funding
Government Entities
Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, SENATE
Registered Lobbyists (1)
STEVEN CRANE — Staff assistant, Senator Barbara Mikulski
IDs
Filing UUID:a5edb8fb-3ed9-4522-bb48-2f17b83460d7
Registrant ID:400927689
Client ID:196249
2025-10-01
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
$0
$50,000
Filing Details
Type: ld2 • Year: 2025 Q3
Specific Issues
Discussed issues related to onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, and potential impact of tariffs on domestic biopharmaceutical manufacturing.; Discussed issues related to onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, and potential impact of tariffs on domestic biopharmaceutical manufacturing.; Discussed issues related to onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, and potential impact of tariffs on domestic biopharmaceutical manufacturing.; Discussed response to Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients
Government Entities
Bureau of Industry and Security (BIS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, State, Dept of (DOS)
Registered Lobbyists (1)
GIL ROTH — not applicable
IDs
Filing UUID:7d6eb167-0413-418d-82f1-b2ba84bc9dd9
Registrant ID:401103605
Client ID:199773
2025-09-29
TAUZIN STRATEGIC NETWORKS
RAZORMETRICS
$37,500
$0
Filing Details
Type: ld2 • Year: 2025 Q3
Specific Issues
Lowering Medicare & Medicaid pharmaceutical spend with advanced cost containment systems; Lowering Medicare & Medicaid pharmaceutical spend with advanced cost containment systems
Government Entities
Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Registered Lobbyists (1)
W.J. TAUZIN
IDs
Filing UUID:49ae1ef3-97ad-47c8-b55f-16ba088e105e
Registrant ID:400786367
Client ID:64818
2025-09-29
PARATEK PHARMACEUTICALS
PARATEK PHARMACEUTICALS
$0
$20,000
Filing Details
Type: ld2 • Year: 2025 Q3
Specific Issues
FY 26 DOD Appropriations FY 26 HHS Appropriations Biodefense Funding
Government Entities
Defense, Dept of (DOD), Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, SENATE
Registered Lobbyists (1)
BENJAMIN NOVAK
IDs
Filing UUID:46cf3dfb-11f1-49a7-a39b-4bbb8a92ffec
Registrant ID:401109327
Client ID:64825
2025-09-27
OLD NORTH STRATEGIES, LLC
FIRST PRINCIPLE STRATEGIES ON BEHALF OF AMERICAN LABORATORIES PHARMA, LLC
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q3
Specific Issues
Manufacturing Domestic Supply Reforms
Registered Lobbyists (1)
JOSEPH KING ●NEW— former Deputy Chief of Staff Congressman Mark Meadows & former Sr. Advisor Congressman Greg Murphy, MD
IDs
Filing UUID:92554f63-ba8d-4819-bd9d-53775086bfc4
Registrant ID:401106174
Client ID:68890
2025-09-26
THE SMITH-FREE GROUP, LLC
SENIOR CARE PHARMACY COALITION
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q3
Specific Issues
Issues pertaining to the long-term care pharmacy industry; Issues pertaining to the long-term care pharmacy industry
Registered Lobbyists (5)
JEFFREY BECKER ●NEW— Coalitions Coordinator, House Republican Conference; Staff Assistant, Rep. Liz CheneyJOHN CHRISTIE ●NEW— Chief of Staff, Rep. Alma Adams; Leg. Director, Rep. Alma Adams; Senior Leg. Assist., Rep. Alma Adams; Leg. Assist., Rep. Alma Adams; Leg. Correspondent/Leg. Aide, Rep. Norma TorresMICHAEL GAFFIN ●NEW— Leg. Director, Sen. Sherrod Brown; Leg. Director, Rep. Rob Andrews; Leg. Asst., Rep. Anna Eshoo; Jr. Leg. Assoc., House Ed and Labor Committee, Rep. George Miller; Staff Asst. Senate HELP Committee, Sen. Edward KennedyMIKE MULLEN ●NEW— Sr. Leg. Asst., Rep. Mike DoyleTREVOR KOLEGO ●NEW— Director of Member Services, Speaker John Boehner; Manager of Member Services, Leader John Boehner; Leg. Director, Rep. Jon Porter; Leg. Assist, Rep. Chris Cannon
IDs
Filing UUID:34e6d9bb-88c7-4850-97d1-da6eb5e5b06e
Registrant ID:35800
Client ID:68877
2025-09-24
DENTONS US LLP
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION (PILMA
$0
$0
Filing Details
Type: ld2 • Year: 2025 Q3
IDs
Filing UUID:e1167f8e-1f7f-4734-852a-e7d95063058d
Registrant ID:36105
Client ID:53148
2025-09-23
MICHAEL BEST STRATEGIES LLC
PUERTO RICO FISCAL AGENCY AND FINANCIAL ADVISORY AUTHORITY
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q3
Specific Issues
Issues related to agencies that affect the island of Puerto Rico, including the DOE, FEMA, DHS, and reshoring pharmaceutical supply chains; Issues related to agencies that affect the island of Puerto Rico, including the DOE, FEMA, DHS, and reshoring pharmaceutical supply chains; Issues related to agencies that affect the island of Puerto Rico, including the DOE, FEMA, DHS, and reshoring pharmaceutical supply chains
Registered Lobbyists (3)
ALEXANDER ANGELSON ●NEW— Special Assistant to the President, Office of Legislative Affairs, Executive Office of the PresidentBRITTAN SPECHT ●NEW— Counsel, Dep Chief of Staff, Hse Speaker; Policy Dir, Dep Policy Dir, Hse Min Leader.; Sr Policy Adv., Hse Maj. Leader; Policy Dr, RSC; Dep Chief of Staff Rep McClintock, Leg Asst & Financial Analyst, Rep. McClintockPRESTON HILL ●NEW— Sr Policy Advisor, House Speaker; Sr. Policy Advisor, Policy Advisor, House Minority Leader; Special Assistant, House Majority Leader
IDs
Filing UUID:51509a7a-be50-48e5-8c42-29dccff8ca94
Registrant ID:401103565
Client ID:68846
2025-09-22
CORNERSTONE GOVERNMENT AFFAIRS, INC.
NERVGEN PHARMA CORP.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q3
Specific Issues
Legislation related to neurotrauma drug approval and neurotrauma medical research.; Legislation related to neurotrauma drug approval and neurotrauma medical research.
Registered Lobbyists (4)
ASHLEY PALMER ●NEW— Dep Asst Sec, Cong. Affairs, HHS; Prof Staff Mem, Senate Approp Cmte;Sr Policy Advisor, Coalitions and Mem Services Svcs Aide, HouseBudget Cmte; Sr Leg Assistant, Leg Asst, House Mem Office (Boehner);Leg Asst, Staff Asst, House Mem Office (Putnam)CHRISTOPHER HODGSON ●NEW— Legislative Assistant (Scalise), Floor Assistant & Deputy Floor Director for House Majority Whip (Scalise), Deputy Director & Director of Legislative Affairs (Pence)JONATHAN MILLER ●NEWSUSAN SWEAT ●NEW— LC, LA & LD House Office (Wicker); LD Senate Member Office (Wicker)
IDs
Filing UUID:957cf25c-d0de-49e6-8ed6-c2cc4da35e99
Registrant ID:75557
Client ID:211044
2025-09-22
MEDSECUREAN.COM
LUPIN PHARMACEUTICALS
$14,000
$0
Filing Details
Type: ld2 • Year: 2025 Q3
Specific Issues
Generic Industry Sustainability and tariifs broadly.; Tarrifs - generic medicine
Government Entities
Commerce, Dept of (DOC), Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), White House Office, U.S. Trade Representative (USTR)
Registered Lobbyists (1)
KATHLEEN JAEGER ●NEW
IDs
Filing UUID:fb336b40-a887-4e31-8559-9688a995b3cc
Registrant ID:401108536
Client ID:68809
2025-09-21
MEDSECUREAN.COM
INDIAN PHARMACEUTICAL ALLIANCE(FORMERLY INDIAN PHARMACEUTICAL ASSOCIATION)
$15,000
$0
Filing Details
Type: ld2 • Year: 2025 Q3
Specific Issues
The Indian Pharmaceutical Alliance (IPA) is dedicated to ensuring a level playing field in the U.S. pharmaceutical market and upholding the principles of the U.S. Hatch-Waxman Act to balance innovation with access. IPA members supply nearly 50% of Medicare Prescriptions, and of the top 10 U.S. therapeutic categories, the companies supply more than half of the prescriptions for 5 of the top 10 categories-ranging up to 60%. IPA members seek to explore U.S. - India supply chain resiliency partnership, and address affordable medicine sustainability reform measures. IPA actively supports targeted reforms to enhance the sustainability of the generic drug industry. Specifically, IPA advocates for substantial reforms of Pharmacy Benefit Managers (PBMs) and Group Purchasing Organizations (GPOs) to ensure transparent pricing and fair market practices that benefit consumers. Additionally, IPA champions efforts to close loopholes in the Hatch-Waxman Act that delay generic drug entry, facilitating timely access to affordable medications. These reforms are crucial for maintaining industry sustainability, reducing healthcare costs, and ensuring that effective, affordable treatment options remain accessible to all Americans. IPAs efforts underscore its pivotal role in promoting a healthy future for all Americans through enhanced access to affordable medicine and a robust, enduring pharmaceutical industry.; Indian Pharmaceutical Alliance is a trade association in India, representing key innovative and affordable medicine manufacturers. These manufacturers supply nearly 50% of Medicare Prescriptions, and of the top 10 U.S. therapeutic categories, the companies supply more than half of the prescriptions for 5 of the top 10 categories-ranging up to 60%. IPA members seek to explore U.S. - India supply chain resiliency partnership, and address affordable medicine sustainability reform measures.
Government Entities
Commerce, Dept of (DOC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office, Natl Economic Council (NEC), Natl Security Council (NSC)
Registered Lobbyists (1)
KATHLEEN JAEGER ●NEW
IDs
Filing UUID:6f393ffc-2b2e-49a9-a9bb-79665bbc2e69
Registrant ID:401108536
Client ID:60141
2025-09-19
CORCORAN & ASSOCIATES, INC. DBA CORCORAN PARTNERS
ORCHARD THERAPEUTICS NORTH AMERICA
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q3
Specific Issues
Issues around health and pharmaceuticals; Issues around health and pharmaceuticals; Issues around health and pharmaceuticals
Registered Lobbyists (2)
MICHAEL CORCORAN ●NEWROBERT BLAIR ●NEW
IDs
Filing UUID:07a056c5-6a28-49b5-8a19-1079f55ddd2e
Registrant ID:401109009
Client ID:65681
2025-09-17
MARSHALL & POPP, LLC
CSL BEHRING
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q3
Specific Issues
Issues related to pharmaceutical manufacturing, drug pricing, trade and tariffs.; Issues related to pharmaceutical manufacturing, drug pricing, trade and tariffs.
Registered Lobbyists (2)
HAZEN MARSHALL ●NEW— Policy Director-Senate Majority Leader Mitch McConnell; Staff Director, Senate Budget Committee-Senator Don Nickles; Deputy Chief of Staff/Economist, Office of Assistant Majority Leader-Senator Don Nickles; Legislative Assistant-Senator Don NicklesMONICA POPP ●NEW— Chief of Staff/Deputy Chief of Staff, Office of Senate Republican Whip John Cornyn; Professional Staff Member, U.S. House of Representatives-Energy & Commerce Committee; Legislative Assistant, Senator Jim DeMint
IDs
Filing UUID:5c1abbc2-8016-41f7-8fe2-3599654c3c35
Registrant ID:401105121
Client ID:68762
2025-09-15
GREENBERG TRAURIG, LLP
ONO PHARMACEUTICAL CO., LTD (FORMERLY ONO PHARMA USA)
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q3
Specific Issues
Legislative and regulator actions relating to drug approvals Issues relating to Pharmaceutical Manufacturing and Development; Legislative and regulator actions relating to drug approvals Issues relating to Pharmaceutical Manufacturing and Development
Registered Lobbyists (3)
CHARLES BASS ●NEW— U.S. Congressman (97 - 07) & (11 - 13)ROBERT MANGAS ●NEWRODNEY FRELINGHUYSEN ●NEW— U.S. Congressman (1995 - 2019)
IDs
Filing UUID:10610252-e479-4f37-9899-d406adf755f0
Registrant ID:16896
Client ID:52685
2025-09-09
BROWNSTEIN HYATT FARBER SCHRECK, LLP
CARDINAL HEALTH, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q3
Specific Issues
General issues affecting the health care industry such as drug pricing, pharmaceutical drugs, medical devices, workforce shortages, and product shortages.
Registered Lobbyists (6)
AARON CUMMINGS ●NEW— Chief of Staff - Sen. Chuck Grassley; Chief Counsel, Constitution/Crime Counsel - Senate Judiciary Committee (Sen. Chuck Grassley)JAMES FLOOD ●NEW— Counsel - Senate Judiciary Committee (Sen. Schumer)SCOTT DOUGLAS ●NEWSTEPHEN HOLLAND ●NEW— Senior Health Counsel, Health Counsel - House Energy and Commerce Committee (Rep. Frank Pallone); Counsel, Legislative Assistant - Rep. Kurt SchraderTIM SHADYAC ●NEWTRACY TOLK ●NEW— Senior Policy Advisor, Senior Legislative Assistant - Rep. Jay Inslee; Senior Legislative Assistant, Legislative Assistant - Rep. Jim Davis
IDs
Filing UUID:2626788b-43cf-4857-85a7-fef0c9b67343
Registrant ID:7257
Client ID:68614
2025-09-08
TALLEY STRATEGIES LLC
TEVA PHARMACEUTICALS USA, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q3
Specific Issues
Issues related to pharmaceutical drug pricing; Issues related to pharmaceutical drug pricing
Registered Lobbyists (1)
AMBER TALLEY ●NEW— Senior Counsel/ Investigator, Senate Special Committee on Aging; Legislative Director, Chief of Staff, Rep. Jason Chaffetz; Counsel, House Oversight Committee
IDs
Filing UUID:b83f409b-3e87-4419-89ec-670d9b8c4388
Registrant ID:401109270
Client ID:68590
2025-09-05
EXECUTIVE STRATEGIES, LTD. CO.
SENTINEL API GROUP, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q3
Specific Issues
BIOSECURE Act implementation (H.R.8333) restricting Chinese pharmaceutical supply chains and supporting domestic API manufacturing. SBIR/STTR reauthorization (S.1573, H.R.3169) for pharmaceutical manufacturing eligibility. Strategic API Reserve funding under August 2025 Executive Order. FDA regulatory reforms including PreCheck Program and expedited facility approvals. Defense Production Act Title III pharmaceutical investments and Defense Manufacturing Community Support Program inclusion. HHS, ASPR, and BARDA appropriations for domestic manufacturing infrastructure.; BIOSECURE Act implementation (H.R.8333) restricting Chinese pharmaceutical supply chains and supporting domestic API manufacturing. SBIR/STTR reauthorization (S.1573, H.R.3169) for pharmaceutical manufacturing eligibility. Strategic API Reserve funding under August 2025 Executive Order. FDA regulatory reforms including PreCheck Program and expedited facility approvals. Defense Production Act Title III pharmaceutical investments and Defense Manufacturing Community Support Program inclusion. HHS, ASPR, and BARDA appropriations for domestic manufacturing infrastructure.; BIOSECURE Act implementation (H.R.8333) restricting Chinese pharmaceutical supply chains and supporting domestic API manufacturing. SBIR/STTR reauthorization (S.1573, H.R.3169) for pharmaceutical manufacturing eligibility. Strategic API Reserve funding under August 2025 Executive Order. FDA regulatory reforms including PreCheck Program and expedited facility approvals. Defense Production Act Title III pharmaceutical investments and Defense Manufacturing Community Support Program inclusion. HHS, ASPR, and BARDA appropriations for domestic manufacturing infrastructure.; BIOSECURE Act implementation (H.R.8333) restricting Chinese pharmaceutical supply chains and supporting domestic API manufacturing. SBIR/STTR reauthorization (S.1573, H.R.3169) for pharmaceutical manufacturing eligibility. Strategic API Reserve funding under August 2025 Executive Order. FDA regulatory reforms including PreCheck Program and expedited facility approvals. Defense Production Act Title III pharmaceutical investments and Defense Manufacturing Community Support Program inclusion. HHS, ASPR, and BARDA appropriations for domestic manufacturing infrastructure.; BIOSECURE Act implementation (H.R.8333) restricting Chinese pharmaceutical supply chains and supporting domestic API manufacturing. SBIR/STTR reauthorization (S.1573, H.R.3169) for pharmaceutical manufacturing eligibility. Strategic API Reserve funding under August 2025 Executive Order. FDA regulatory reforms including PreCheck Program and expedited facility approvals. Defense Production Act Title III pharmaceutical investments and Defense Manufacturing Community Support Program inclusion. HHS, ASPR, and BARDA appropriations for domestic manufacturing infrastructure.; BIOSECURE Act implementation (H.R.8333) restricting Chinese pharmaceutical supply chains and supporting domestic API manufacturing. SBIR/STTR reauthorization (S.1573, H.R.3169) for pharmaceutical manufacturing eligibility. Strategic API Reserve funding under August 2025 Executive Order. FDA regulatory reforms including PreCheck Program and expedited facility approvals. Defense Production Act Title III pharmaceutical investments and Defense Manufacturing Community Support Program inclusion. HHS, ASPR, and BARDA appropriations for domestic manufacturing infrastructure.
Registered Lobbyists (1)
TYLER BEAVER ●NEW
IDs
Filing UUID:b1170da2-64e5-4144-8dd7-f46aa80764dd
Registrant ID:401109694
Client ID:68576
2025-09-04
CGCN GROUP, LLC
FRESENIUS KABI USA, LLC
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q3
Specific Issues
Sec. 232 investigation on pharmaceutical sector, tariffs, Buy America policies, Most Favored Nations Executive Order, reciprocal tariffs, essential medicines drug shortages related to trade agreements. U.S. manufacturing incentives. Buy America legislation, tariffs, tax incentives, regulatory barriers to generic and biosimilar launches, patent waivers. Section 232 investigation into pharmaceuticals and unfair trade practices.; Sec. 232 investigation on pharmaceutical sector, tariffs, Buy America policies, Most Favored Nations Executive Order, reciprocal tariffs, essential medicines drug shortages related to trade agreements. U.S. manufacturing incentives. Buy America legislation, tariffs, tax incentives, regulatory barriers to generic and biosimilar launches, patent waivers. Section 232 investigation into pharmaceuticals and unfair trade practices.; Sec. 232 investigation on pharmaceutical sector, tariffs, Buy America policies, Most Favored Nations Executive Order, reciprocal tariffs, essential medicines drug shortages related to trade agreements. U.S. manufacturing incentives. Buy America legislation, tariffs, tax incentives, regulatory barriers to generic and biosimilar launches, patent waivers. Section 232 investigation into pharmaceuticals and unfair trade practices.; Sec. 232 investigation on pharmaceutical sector, tariffs, Buy America policies, Most Favored Nations Executive Order, reciprocal tariffs, essential medicines drug shortages related to trade agreements. U.S. manufacturing incentives. Buy America legislation, tariffs, tax incentives, regulatory barriers to generic and biosimilar launches, patent waivers. Section 232 investigation into pharmaceuticals and unfair trade practices.
Registered Lobbyists (2)
JILL HAMAKER ●NEWMARTHA MILLER ●NEW— Confidential Assistant, U.S. Department of Education, 2017-2019; Deputy Director of Scheduling, Sen. Ted Cruz (TX), 2019-2020; Scheduler, Rep. Warren Davidson (OH-08), 2020-2022.